Efficacy and Safety of Lapatinib Treatment in Trastuzumab Pretreated Patients with HER2 Positive Metastatic Breast Cancer - An Analysis of IntERB Registry in the Czech Republic

被引：0
|
作者：
Grell, P. [1 ]
Kandrnal, V. [2 ]
Bortlicek, Z. [2 ]
Vyzula, R. [1 ]
机构：
[1] Masaryk Mem Canc Inst, Brno, Czech Republic
[2] Masaryk Univ, Inst Biostat & Anal, Brno, Czech Republic
来源：
EUROPEAN JOURNAL OF CANCER | 2012年 / 48卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S94 / S95
页数：2
相关论文
共 50 条
  • [31] Trastuzumab and lapatinib in HER2-positive metastatic colorectal cancer
    Biswas, Bivas
    Rastogi, Sameer
    Batra, Atul
    Ganguly, Sandip
    NATIONAL MEDICAL JOURNAL OF INDIA, 2016, 29 (04): : 219 - 220
  • [32] Correlation of trastuzumab treatment benefit with quantitative HER2 expression levels in HER2 positive metastatic breast cancer.
    Bachmeier, Beatrice
    Sperinde, Jeff
    Weidler, Jodi Marie
    Lie, Yolanda
    Chenna, Ahmed
    Winslow, John
    Engel, Jutta
    Schubert-Fritschle, Gabriele
    Sommerhoff, Christian
    Petropoulos, Christos J.
    Bates, Michael Patrick
    Huang, Weidong
    Nerlich, Andreas
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [33] EFFICACY OF TRASTUZUMAB CONTAINING RETREATMENT AFTER PROGRESSION ON LAPATINIB THERAPY IN JAPANESE PATIENTS WITH HER2-POSITIVE METASTATIC BREAST CANCER
    Hattori, M.
    Iwata, H.
    Fujita, T.
    Sawaki, M.
    Kondo, N.
    Horio, A.
    Muro, K.
    ANNALS OF ONCOLOGY, 2012, 23 : 139 - 139
  • [34] Safety of the combination of lapatinib (L) plus trastuzumab (T) in patients (pts) with HER2-Positive (+) metastatic breast cancer (MBC)
    Storniolo, A.
    Koehler, M.
    Preston, A.
    Rappold, E.
    Byrne, J.
    Stein, S.
    Ewer, M.
    EJC SUPPLEMENTS, 2007, 5 (04): : 187 - 187
  • [35] Lapatinib with trastuzumab for heavily treated HER2-positive metastatic breast cancer (mBC).
    Sotelo, Miguel J.
    Manso, Luis
    Garcia Saenz, Jose Angel
    Ciruelos, Eva M.
    Moreno, Fernando
    Mendiola, Cesar
    Callata, Hector
    Ghanem, Ismael
    Cabezas, Santiago
    Gonzalez-Larriba, Jose-Luis
    Diaz Rubio, Eduardo
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [36] Lapatinib plus trastuzumab for HER-2 positive metastatic breast cancer: experience of use
    Garcia Munoz, C.
    Cortijo Cascajares, S.
    Canamares Orbis, I.
    Goyache Goni, M. D. P.
    Ferrari Piquero, J. M.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2013, 35 (05) : 892 - 893
  • [37] Efficacy of trastuzumab-based therapy after disease progression on lapatinib based therapy in heavily pretreated HER2-positive metastatic breast cancer patients.
    Uncu, Dogan
    Bayoglu, Ibrahim Vedat
    Arslan, Ulku Yalcintas
    Kucukoner, Mehmet
    Artac, Mehmet
    Koca, Dogan
    Oguz, Arzu
    Demirci, Umut
    Arpaci, Erkan
    Dogan, Mutlu
    Kucukzeybek, Yuksel
    Turker, Ibrahim
    Isikdogan, Abdurrahman
    Guler, Tunc
    Zengin, Nurullah
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [38] Outcomes of patients with HER2 positive metastatic breast cancer treated with low dose or metronomic lapatinib
    Mathew, S. P.
    Avaronnan, M.
    Shenoy, P. K.
    Devi R, N.
    ANNALS OF ONCOLOGY, 2022, 33 : S1439 - S1439
  • [39] Phase II trial of lapatinib and everolimus for HER2 positive metastatic breast cancer
    Barr, J. A.
    Sharma, P.
    Fabian, C. J.
    Yeh, H.
    Baccaray, S.
    Springer, M.
    Khan, Q. J.
    CANCER RESEARCH, 2016, 76
  • [40] A phase II trial of lapatinib and everolimus for HER2 positive metastatic breast cancer
    Rooney, Anthony
    Sharma, Priyanka
    O'Dea, Anne P.
    Nye, Lauren
    Elia, Manana
    He, Jianghua
    Fabian, Carol
    Khan, Qamar
    CANCER RESEARCH, 2022, 82 (04)
12345